Murciano-Goroff, Y. R., Warner, A. B. & Wolchok, J. D. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 30, 507–519 (2020).
Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).
Cameron, F., Whiteside, G. & Perry, C. Ipilimumab: first global approval. Drugs 71, 1093–1104 (2011).
Mullard, A. FDA approves first CAR T therapy. Nat. Rev. Drug. Discov. 16, 669–669 (2017).
Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug. Discov. 18, 175–196 (2019).
Ledford, H., Else, H. & Warren, M. Cancer immunologists scoop medicine Nobel prize. Nature 562, 20–21 (2018).
Katze, M. G., He, Y. & Gale, M. Jr. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2, 675–687 (2002).
Murgas, P. et al. A filamentous bacteriophage targeted to carcinoembryonic antigen induces tumor regression in mouse models of colorectal cancer. Cancer Immunol. Immunother. 67, 183–193 (2018).
Lizotte, P. H. et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat. Nanotechnol. 11, 295–303 (2016).
Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015).
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188–2205 (2023).
Chao, Y. & Liu, Z. Biomaterials tools to modulate the tumour microenvironment in immunotherapy. Nat. Rev. Bioeng. 1, 125–138 (2023).
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414 (2015).
Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B 147, 258–267 (1957).
Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014).
Quesada, J. R. et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 68, 493–497 (1986).
Hauschild, A. et al. Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112, 982–994 (2008).
Wills, R. J. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet. 19, 390–399 (1990).
Brown, M. C. et al. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci. Transl. Med. 9, eaan4220 (2017).
Sabree, S. A. et al. Monocytes exposed to immune complexes reduce pDC type 1 interferon response to vidutolimod. Vaccines 9, 982 (2021).
Lebel, M.-È. et al. Potentiating cancer immunotherapy using papaya mosaic virus-derived nanoparticles. Nano Lett. 16, 1826–1832 (2016).
Mao, C., Beiss, V., Fields, J., Steinmetz, N. F. & Fiering, S. Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent Toll-like receptors. Biomaterials 275, 120914 (2021).
Zeltins, A. Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 53, 92–107 (2013).
Coley, W. B. II. Contribution to the knowledge of sarcoma. Ann. Surg. 14, 199–220 (1891).
Starnes, C. O. Coley’s toxins. Nature 360, 23 (1992).
Ehrlich, P. Ueber den jetzigen Stand Der Karzinomforchung. Nederl. Tijdschr. Geneeskd. 53, 273–290 (1909).
Burnet, F. M. Immunological surveillance in neoplasia. Transpl. Rev. 7, 3–25 (1971).
Burnet, M. Cancer — a biological approach: III. Viruses associated with neoplastic conditions. IV. Practical applications. Br. Med. J. 1, 841 (1957).
Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558–576 (2021).
Sheen, M. R. & Fiering, S. In situ vaccination: harvesting low hanging fruit on the cancer immunotherapy tree. WIREs Nanomed. Nanobiotechnol. 11, e1524 (2019).
Russell, S. J., Peng, K.-W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658–670 (2012).
Breitbach, C. J. et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99–102 (2011).
Maroun, J. et al. Designing and building oncolytic viruses. Future Virol. 12, 193–213 (2017).
Wang, Y. L., Peng, H. H., Su, S. Y. & Lin, C. T. Combined immunotherapy (OK-432, IL-2) with chemotherapy decrease the recurrence rate in advanced ovarian cancer. Reprod. Sci. 26, 244–249 (2019).
Shalhout, S. Z., Miller, D. M., Emerick, K. S. & Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160–177 (2023).
Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure — an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806–813 (2004).
Puts, M. T. E. et al. Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann. Oncol. 25, 564–577 (2014).
Chung, Y. H. et al. Integrating plant molecular farming and materials research for next-generation vaccines. Nat. Rev. Mater. 7, 372–388 (2022).
Beijerinck, M. W. Ueber ein contagium vivum fluidum als Ursache der Fleckenkrankheit der Tabaksblatter [transl. Concerning a contagium vivum fluidum as cause of the spot disease of tobacco leaves.] Verhandelingen der Koninklyke akademie van Wettenschappen te Amsterdam [transl. American Phytopathological Society] https://dwc.knaw.nl/DL/publications/PU00011860.pdf (1898).
Scholthof, K. B. Tobacco mosaic virus: a model system for plant biology. Annu. Rev. Phytopathol. 42, 13–34 (2004).
Lomonossoff, G. P. & Wege, C. TMV particles: the journey from fundamental studies to bionanotechnology applications. Adv. Virus Res. 102, 149–176 (2018).
Kausche, G. A., Pfankuch, E. & Ruska, H. Die Sichtbarmachung von pflanzlichem virus im Übermikroskop. Naturwissenschaften 27, 292–299 (1939).
Caspar, D. L. & Klug, A. Physical principles in the construction of regular viruses. Cold Spring Harb. Symp. Quant. Biol. 27, 1–24 (1962).
Strable, E. & Finn, M. G. Chemical modification of viruses and virus-like particles. Curr. Top. Microbiol. Immunol. 327, 1–21 (2009).
Wang, Q., Lin, T., Tang, L., Johnson, J. E. & Finn, M. G. Icosahedral virus particles as addressable nanoscale building blocks. Angew. Chem. Int. Edn Engl. 41, 459–462 (2002).
Maheshri, N., Koerber, J. T., Kaspar, B. K. & Schaffer, D. V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198–204 (2006).
McNeale, D., Dashti, N., Cheah, L. C. & Sainsbury, F. Protein cargo encapsulation by virus-like particles: strategies and applications. Wiley Interdisc. Rev. Nanomed. Nanobiotechnol. 15, e1869 (2023).
Bischoff, A. J. et al. Protein-based model for energy transfer between photosynthetic light-harvesting complexes is constructed using a direct protein–protein conjugation strategy. J. Am. Chem. Soc. 145, 15827–15837 (2023).
Dai, J. et al. A membrane-associated light-harvesting model is enabled by functionalized assemblies of gene-doubled TMV proteins. Small 19, e2207805 (2023).
Oh, D. et al. Biologically enhanced cathode design for improved capacity and cycle life for lithium–oxygen batteries. Nat. Commun. 4, 2756 (2013).
Tseng, R. J. et al. Digital memory device based on tobacco mosaic virus conjugated with nanoparticles. Nat. Nanotechnol. 1, 72–77 (2006).
Carette, N. et al. A virus-based biocatalyst. Nat. Nanotechnol. 2, 226–229 (2007).
Patterson, D. P., Schwarz, B., Waters, R. S., Gedeon, T. & Douglas, T. Encapsulation of an enzyme cascade within the bacteriophage P22 virus-like particle. ACS Chem. Biol. 9, 359–365 (2014).
Bucci, M. Milestones: First recombinant DNA vaccine for HBV. Nature https://www.nature.com/articles/d42859-020-00016-5 (2020).
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G. & Hall, B. D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298, 347–350 (1982).
Crystal, R. G. Adenovirus: the first effective in vivo gene delivery vector. Hum. Gene Ther. 25, 3–11 (2014).
Zabner, J. et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75, 207–216 (1993).
Garber, K. China approves world’s first oncolytic virus therapy for cancer treatment. J. Natl Cancer Inst. 98, 298–300 (2006).
Greig, S. L. Talimogene laherparepvec: first global approval. Drugs 76, 147–154 (2016).
Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
Shahrivarkevishahi, A. et al. Virus-like particles: a self-assembled toolbox for cancer therapy. Mater. Today Chem. 24, 100808 (2022).
Bachmann, M. F. et al. The influence of antigen organization on B cell responsiveness. Science 262, 1448–1451 (1993).
Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787–796 (2010).
Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug. Discov. 14, 642–662 (2015).
Alberts, P., Tilgase, A., Rasa, A., Bandere, K. & Venskus, D. The advent of oncolytic virotherapy in oncology: the Rigvir® story. Eur. J. Pharmacol. 837, 117–126 (2018).
Liang, M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr. Cancer Drug. Targets 18, 171–176 (2018).
Fukuhara, H., Ino, Y. & Todo, T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 107, 1373–1379 (2016).
Chaurasiya, S., Chen, N. G. & Fong, Y. Oncolytic viruses and immunity. Curr. Opin. immunology 51, 83–90 (2018).
Prestwich, R. J. et al. Oncolytic viruses: a novel form of immunotherapy. Expert. Rev. Anticancer. Ther. 8, 1581–1588 (2008).
Chiocca, E. A. & Rabkin, S. D. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol. Res. 2, 295–300 (2014).
Aurelian, L. Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther. 9, 2627–2637 (2016).
Tian, Y., Xie, D. & Yang, L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal. Transduct. Target. Ther. 7, 117 (2022).
Jhawar, S. R. et al. Oncolytic viruses — natural and genetically engineered cancer immunotherapies. Front. Oncol. 7, 202 (2017).
Anderson, B. D., Nakamura, T., Russell, S. J. & Peng, K. W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 64, 4919–4926 (2004).
Malissen, N. et al. HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma. Oncoimmunology 8, e1665976 (2019).
Oshima, T. et al. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers. Mol. Cancer 12, 60 (2013).
Yamada, M. et al. Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma. Surg. Today 48, 510–516 (2018).
Davidson, B. et al. αV- and β1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol. Oncol. 90, 248–257 (2003).
Kohlhapp, F., Zloza, A. & Kaufman, H. Talimogene laherparepvec (T-VEC) as cancer immunotherapy. Drugs Today 51, 549–558 (2015).
Dörig, R. E., Marcil, A., Chopra, A. & Richardson, C. D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75, 295–305 (1993).
Carlsten, M. et al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J. Immunol. 183, 4921–4930 (2009).
Yang, M. et al. A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy. Cancer Biol. Ther. 18, 833–840 (2017).
Puig-Saus, C. et al. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther. 21, 767–774 (2014).
Martinez-Velez, N. et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat. Commun. 10, 2235 (2019).
Judd, J. et al. Tunable protease-activatable virus nanonodes. ACS Nano 8, 4740–4746 (2014).
van der Meel, R. et al. Smart cancer nanomedicine. Nat. Nanotechnol. 14, 1007–1017 (2019).
Shi, Y. & Lammers, T. Combining nanomedicine and immunotherapy. Acc. Chem. Res. 52, 1543–1554 (2019).
Bhagwat, A. S. & Vakoc, C. R. Targeting transcription factors in cancer. Trends Cancer 1, 53–65 (2015).
Critchley-Thorne, R. J. et al. Impaired interferon signaling is a common immune defect in human cancer. Proc. Natl Acad. Sci. USA 106, 9010–9015 (2009).
Matveeva, O. V. & Chumakov, P. M. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses. Rev. Med. Virol. 28, e2008 (2018).
Kaloni, D., Diepstraten, S. T., Strasser, A. & Kelly, G. L. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis 28, 20–38 (2023).
Trisciuoglio, D. et al. BCL-X overexpression promotes tumor progression-associated properties. Cell Death Dis. 8, 3216 (2017).
Mansour, M., Palese, P. & Zamarin, D. Oncolytic specificity of newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J. Virol. 85, 6015–6023 (2011).
Rodriguez, R. et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559–2563 (1997).
DeWeese, T. L. et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61, 7464–7472 (2001).
Gujar, S., Pol, J. G., Kim, Y., Lee, P. W. & Kroemer, G. Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies. Trends Immunol. 39, 209–221 (2018).
Kelly, K. R. et al. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia 32, 230–233 (2018).
Feist, M. et al. Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Ther. 28, 98–111 (2021).
Chouljenko, D. V. et al. Induction of durable antitumor response by a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. Biomedicines 8, 484 (2020).
Wenthe, J. et al. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40. Cancer Gene Ther. 27, 948–959 (2020).
Ylösmäki, E. et al. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. Mol. Ther. Oncolyt. 20, 459–469 (2021).
Eriksson, E. et al. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment. Gene Ther. 24, 92–103 (2017).
Lee, J.-C. et al. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. Gastrointest. Endosc. 92, 1044–1052.e1041 (2020).
Doronin, K. et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147–6155 (2000).
Barton, K. N. et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther. 13, 347–356 (2006).
Boorjian, S. A. et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 22, 107–117 (2021).
Shin, D. H. et al. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. J. Immunother. Cancer 9, e002086 (2021).
Liu, B. et al. ICP34. 5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292–303 (2003).
Chou, J. & Roizman, B. The gamma 1 (34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc. Natl Acad. Sci. USA 89, 3266–3270 (1992).
Gromeier, M., Lachmann, S., Rosenfeld, M. R., Gutin, P. H. & Wimmer, E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl Acad. Sci. USA 97, 6803–6808 (2000).
Yun, C.-O., Hong, J. & Yoon, A. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Front. Immunol. 13, 953410 (2022).
Smith, T. et al. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus–adenovirus receptor. Mol. Ther. 5, 770–779 (2002).
Groeneveldt, C., van den Ende, J. & van Montfoort, N. Preexisting immunity: barrier or bridge to effective oncolytic virus therapy? Cytokine Growth Factor. Rev. 70, 1–12 (2023).
Wakimoto, H. et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 5, 275–282 (2002).
Nosaki, K. et al. A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity. Mol. Ther. Oncolytics 3, 16022 (2016).
Huang, H. W. et al. Full encapsulation of oncolytic virus using hybrid erythroctye-liposome membranes for augmented anti-refractory tumor effectiveness. Nano Today 47, 101671 (2022).
Xia, M. et al. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy. J. Exp. Clin. Cancer Res. 38, 408 (2019).
Rojas, L. A. et al. Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery. J. Control. Rel. 237, 78–88 (2016).
Martinez-Quintanilla, J., He, D., Wakimoto, H., Alemany, R. & Shah, K. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol. Ther. 23, 108–118 (2015).
Hammad, M. et al. Neural stem cells improve the delivery of oncolytic chimeric orthopoxvirus in a metastatic ovarian cancer model. Mol. Ther. Oncolyt. 18, 326–334 (2020).
Cornejo, Y. et al. NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy. Oncotarget 11, 4693 (2020).
Andtbacka, R. H. I. et al. Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma. J. Clin. Oncol. 39, 3829–3838 (2021).
Breitbach, C. J., Moon, A., Burke, J., Hwang, T. H. & Kirn, D. H. A phase 2, open-label, randomized study of pexa-vec (JX-594) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma. Methods Mol. Biol. 1317, 343–357 (2015).
Lin, D., Shen, Y. & Liang, T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal. Transduct. Target. Ther. 8, 156 (2023).
Alonso-Miguel, D. et al. Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer. J. Immunother. Cancer 10, e004044 (2022).
Mao, C. et al. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade. J. Immunother. Cancer 10, e005834 (2022).
Shukla, S., Wang, C., Beiss, V. & Steinmetz, N. F. Antibody response against cowpea mosaic viral nanoparticles improves in situ vaccine efficacy in ovarian cancer. ACS Nano 14, 2994–3003 (2020).
Valdivia, G. et al. Neoadjuvant intratumoral immunotherapy with cowpea mosaic virus induces local and systemic antitumor efficacy in canine mammary cancer patients. Cells 12, 2241 (2023).
Davies, J. W. Molecular Plant Virology (CRC Press, 1985).
Yang, S. et al. Crystal structure of the coat protein of the flexible filamentous papaya mosaic virus. J. Mol. Biol. 422, 263–273 (2012).
Denis, J. et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26, 3395–3403 (2008).
Lebel, M. E. et al. Nanoparticle adjuvant sensing by TLR7 enhances CD8+ T cell-mediated protection from Listeria monocytogenes infection. J. Immunol. 192, 1071–1078 (2014).
Mathieu, C., Rioux, G., Dumas, M. C. & Leclerc, D. Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge. Nanomedicine 9, 839–848 (2013).
Lee, K. L. et al. Combination of plant virus nanoparticle-based in situ vaccination with chemotherapy potentiates antitumor response. Nano Lett. 17, 4019–4028 (2017).
Eriksson, F. et al. Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. J. Immunol. 182, 3105–3111 (2009).
Tian, Y. et al. Probing the endocytic pathways of the filamentous bacteriophage in live cells using ratiometric pH fluorescent indicator. Adv. Healthc. Mater. 4, 413–419 (2015).
Prangishvili, D., Forterre, P. & Garrett, R. A. Viruses of the Archaea: a unifying view. Nat. Rev. Microbiol. 4, 837–848 (2006).
Krupovic, M., Cvirkaite-Krupovic, V., Iranzo, J., Prangishvili, D. & Koonin, E. V. Viruses of Archaea: structural, functional, environmental and evolutionary genomics. Virus Res. 244, 181–193 (2018).
Young, T. D. A. M. Viruses: making friends with old foes. Science 312, 873–875 (2006).
De Lombaerde, E., De Wever, O. & De Geest, B. G. Delivery routes matter: safety and efficacy of intratumoral immunotherapy. Biochim. Biophys. Acta Rev. Cancer 1875, 188526 (2021).
Tariq, H., Batool, S., Asif, S., Ali, M. & Abbasi, B. H. Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases. Front. Microbiol. 12, 790121 (2021).
Sabree, S. A. et al. Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. J. Immunother. Cancer 9, e002484 (2021).
Cai, H., Shukla, S. & Steinmetz, N. F. The antitumor efficacy of CpG oligonucleotides is improved by encapsulation in plant virus-like particles. Adv. Funct. Mater. 30, 1908743 (2020).
Jung, E., Chung, Y. H. & Steinmetz, N. F. TLR agonists delivered by plant virus and bacteriophage nanoparticles for cancer immunotherapy. Bioconjug. Chem. 34, 1596–1605 (2023).
Storni, T. et al. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 172, 1777–1785 (2004).
Krug, A. et al. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur. J. Immunol. 31, 2154–2163 (2001).
Mutwiri, G. K., Nichani, A. K., Babiuk, S. & Babiuk, L. A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J. Control. Rel. 97, 1–17 (2004).
Cheng, Y. et al. In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. J. Immunother. Cancer 8, e000940 (2020).
Lemke-Miltner, C. D. et al. Antibody opsonization of a TLR9 agonist-containing virus-like particle enhances in situ immunization. J. Immunol. 204, 1386–1394 (2020).
Bakhos Jneid, A. B. et al. Selective STING stimulation in dendritic cells primes antitumor T cell responses. Sci. Immunol. 8, 1–17 (2023).
Cerullo, V. et al. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol. Ther. 20, 2076–2086 (2012).
Zhang, P., Han, X., Tan, W., Chen, D. & Sun, Q. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus. Thorac. Cancer 14, 246–253 (2023).
Thorne, S. H. Adding STING to the tale of oncolytic virotherapy. Trends Cancer 2, 67–68 (2016).
Westcott, P. M. K. et al. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity. Nat. Genet. 55, 1686–1695 (2023).
Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116–120 (2017).
Hom, V., Karonis, E., Sigidi, T. & Cawley, K. Development of a nursing policy for the administration of an oncolytic virus in the outpatient setting. Semin. Oncol. Nurs. 35, 150928 (2019).
Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug. Discov. 18, 197–218 (2019).
Bommareddy, P. A.-O., Aspromonte, S., Zloza, A., Rabkin, S. A.-O. & Kaufman, H. L. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci. Transl. Med. 10, eaau0417 (2018).
Wang, C. & Steinmetz, N. F. A combination of cowpea mosaic virus and immune checkpoint therapy synergistically improves therapeutic efficacy in three tumor models. Adv. Funct. Mater. 30, 2002299 (2020).
Passaro, C. et al. Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. Clin. Cancer Res. 25, 290–299 (2019).
Zamarin, D. et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J. Clin. Invest. 128, 1413–1428 (2018).
Shakoora, A. S. et al. Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. J. Immunother. Cancer 9, e002484 (2021).
Yinwen, C. et al. in situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. J. Immunother. Cancer 8, e000940 (2020).
Ribas, A. et al. Overcoming PD-1 blockade resistance with CpG — a Toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma. Cancer Discov. 11, 2998–3007 (2021).
Dummer, R. et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat. Med. 27, 1789–1796 (2021).
Hong, W. X. et al. Intratumoral immunotherapy for early-stage solid tumors. Clin. Cancer Res. 26, 3091–3099 (2020).
Munoz, N. M. et al. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy. J. Immunother. Cancer 9, e001800 (2021).
Mohsen, M. O. et al. In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma. J. Immunother. Cancer 10, e004643 (2022).
Packiam, V. T. et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol. Oncol. 36, 440–447 (2018).
Nassiri, F. et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat. Med. 29, 1370–1378 (2023).
Gallego Perez-Larraya, J. et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N. Engl. J. Med. 386, 2471–2481 (2022).
Fares, J. et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol. 22, 1103–1114 (2021).
Beasley, G. M. et al. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. J. Immunother. Cancer 9, e002203 (2021).
Rudin, C. M. et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin. Cancer Res. 17, 888–895 (2011).
Lutzky, J. et al. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. J. Cancer Res. Clin. 1449, 6059–6066 (2023).
Senzer, N. N. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763–5771 (2009).
Andtbacka, R. H. et al. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head Neck 38, 1752–1758 (2016).
Chesney, J. A. et al. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J. Immunother. Cancer 11, e006270 (2023).
Streby, K. A. et al. First-in-human intravenous seprehvir in young cancer patients: a phase 1 clinical trial. Mol. Ther. 27, 1930–1938 (2019).
Streby, K. A. et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin. Cancer Res. 23, 3566–3574 (2017).
Geletneky, K. et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: parvOryx01 protocol. BMC Cancer 12, 99 (2012).
Hwang, T. H. et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol. Ther. 19, 1913–1922 (2011).
Heo, J. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329–336 (2013).
Holloway, R. W. et al. Clinical activity of olvimulogene nanivacirepvec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer: the nonrandomized phase 2 VIRO-15 clinical trial. JAMA Oncol. 9, 903–908 (2023).
Le Gall, O. et al. Picornavirales, a proposed order of positive-sense single-stranded RNA viruses with a pseudo-T=3 virion architecture. Arch. Virol. 153, 715–727 (2008).
Lin, T. & Johnson, J. E. Structures of picorna-like plant viruses: implications and applications. Adv. Virus Res. 62, 167–239 (2003).
Brown, M. C. et al. Oncolytic polio virotherapy of cancer. Cancer 120, 3277–3286 (2014).
Walton, R. W., Brown, M. C., Sacco, M. T. & Gromeier, M. Engineered oncolytic poliovirus PVSRIPO subverts MDA5-dependent innate immune responses in cancer cells. J. Virol. 92, e00879–e00918 (2018).
Lomonossoff, G. P. in Encyclopedia of Virology 569–574 (Elsevier, 2008).
Shukla, S. et al. The unique potency of cowpea mosaic virus (CPMV) in situ cancer vaccine. Biomater. Sci. 8, 5489–5503 (2020).
Beiss, V., Mao, C., Fiering, S. N. & Steinmetz, N. F. Cowpea mosaic virus outperforms other members of the secoviridae as in situ vaccine for cancer immunotherapy. Mol. Pharm. 19, 1573–1585 (2022).
Argos, P., Kamer, G., Nicklin, M. J. H. & Wimmer, E. Similarity in gene organization and homology between proteins of animal picomaviruses and a plant comovirus suggest common ancestry of these virus families. Nucl. Acids Res. 12, 7251–7267 (1984).
Franssen, H., Leunissen, J., Goldbach, R., Lomonossoff, G. & Zimmern, D. Homologous sequences in non-structural proteins from cowpea mosaic virus and picornaviruses. EMBO J. 3, 855–861 (1984).
Beck, M. A. et al. Comoviruses and enteroviruses share a T cell epitope. Virology 186, 238–246 (1992).
Tripathi, N. K. & Shrivastava, A. Recent developments in bioprocessing of recombinant proteins: expression hosts and process development. Front. Bioeng. Biotechnol. 7, 420 (2019).
Wellink, J. Comovirus isolation and RNA extraction. Methods Mol. Biol. 81, 205–209 (1998).
Coalition for Epidemic Preparedness Innovations (CEPI). Plant-based ALiCE® technology could shave weeks off vaccine production. CEPI https://cepi.net/plant-based-alicer-technology-could-shave-weeks-vaccine-production (2024).
Lee, J., Lee, S. K., Park, J. S. & Lee, K. R. Plant-made pharmaceuticals: exploring studies for the production of recombinant protein in plants and assessing challenges ahead. Plant. Biotechnol. Rep. 17, 53–65 (2023).
Alam, A. et al. Technoeconomic modeling of plant-based griffithsin manufacturing. Front. Bioeng. Biotechnol. 6, 102 (2018).
Nandi, S. et al. Techno-economic analysis of a transient plant-based platform for monoclonal antibody production. MAbs 8, 1456–1466 (2016).
Holtz, B. R. et al. Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals. Plant. Biotechnol. J. 13, 1180–1190 (2015).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s44222-024-00231-z